131 related articles for article (PubMed ID: 9862744)
1. Perforin/Fas-ligand double deficiency is associated with macrophage expansion and severe pancreatitis.
Spielman J; Lee RK; Podack ER
J Immunol; 1998 Dec; 161(12):7063-70. PubMed ID: 9862744
[TBL] [Abstract][Full Text] [Related]
2. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism.
Williams NS; Engelhard VH
J Immunol; 1996 Jan; 156(1):153-9. PubMed ID: 8598456
[TBL] [Abstract][Full Text] [Related]
3. TNF contributes to the immunopathology of perforin/Fas ligand double deficiency.
Cretney E; Street SE; Smyth MJ
Immunol Cell Biol; 2002 Oct; 80(5):436-40. PubMed ID: 12225379
[TBL] [Abstract][Full Text] [Related]
4. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells.
Williams NS; Engelhard VH
J Immunol; 1997 Sep; 159(5):2091-9. PubMed ID: 9278294
[TBL] [Abstract][Full Text] [Related]
5. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
[TBL] [Abstract][Full Text] [Related]
6. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome.
Rafi AQ; Zeytun A; Bradley MJ; Sponenberg DP; Grayson RL; Nagarkatti M; Nagarkatti PS
J Immunol; 1998 Sep; 161(6):3077-86. PubMed ID: 9743374
[TBL] [Abstract][Full Text] [Related]
8. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
9. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand.
Miura Y; Thoburn CJ; Bright EC; Hess AD
Biol Blood Marrow Transplant; 2004 Mar; 10(3):156-70. PubMed ID: 14993881
[TBL] [Abstract][Full Text] [Related]
10. Relative perforin- and Fas-mediated lysis in T1 and T2 CD8 effector populations.
Carter LL; Dutton RW
J Immunol; 1995 Aug; 155(3):1028-31. PubMed ID: 7543509
[TBL] [Abstract][Full Text] [Related]
11. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
12. Perforin-deficient CD8+ T cells: in vivo priming and antigen-specific immunity against Listeria monocytogenes.
White DW; MacNeil A; Busch DH; Pilip IM; Pamer EG; Harty JT
J Immunol; 1999 Jan; 162(2):980-8. PubMed ID: 9916723
[TBL] [Abstract][Full Text] [Related]
13. Veto activity of activated bone marrow does not require perforin and Fas ligand.
Chrobak P; Gress RE
Cell Immunol; 2001 Mar; 208(2):80-7. PubMed ID: 11333140
[TBL] [Abstract][Full Text] [Related]
14. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Sep; 7(18):1527-35. PubMed ID: 11021590
[TBL] [Abstract][Full Text] [Related]
15. Independent roles of perforin, granzymes, and Fas in the control of Friend retrovirus infection.
Zelinskyy G; Balkow S; Schimmer S; Schepers K; Simon MM; Dittmer U
Virology; 2004 Dec; 330(2):365-74. PubMed ID: 15567431
[TBL] [Abstract][Full Text] [Related]
16. Perforin expression can define CD8 positive lymphocyte subsets in pigs allowing phenotypic and functional analysis of natural killer, cytotoxic T, natural killer T and MHC un-restricted cytotoxic T-cells.
Denyer MS; Wileman TE; Stirling CM; Zuber B; Takamatsu HH
Vet Immunol Immunopathol; 2006 Apr; 110(3-4):279-92. PubMed ID: 16325923
[TBL] [Abstract][Full Text] [Related]
17. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.
Tsung K; Dolan JP; Tsung YL; Norton JA
Cancer Res; 2002 Sep; 62(17):5069-75. PubMed ID: 12208763
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl 2,2-dichlorovinyl phosphate (DDVP) markedly inhibits activities of natural killer cells, cytotoxic T lymphocytes and lymphokine-activated killer cells via the Fas-ligand/Fas pathway in perforin-knockout (PKO) mice.
Li Q; Nakadai A; Takeda K; Kawada T
Toxicology; 2004 Nov; 204(1):41-50. PubMed ID: 15369847
[TBL] [Abstract][Full Text] [Related]
19. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
Lee SH; Bar-Haim E; Machlenkin A; Goldberger O; Volovitz I; Vadai E; Tzehoval E; Eisenbach L
Cancer Gene Ther; 2004 Mar; 11(3):237-48. PubMed ID: 14739939
[TBL] [Abstract][Full Text] [Related]
20. Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells.
Yanai F; Ishii E; Kojima K; Hasegawa A; Azuma T; Hirose S; Suga N; Mitsudome A; Zaitsu M; Ishida Y; Shirakata Y; Sayama K; Hashimoto K; Yasukawa M
J Immunol; 2003 Feb; 170(4):2205-13. PubMed ID: 12574394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
